+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the EuroHeart program, an observational and prospective multicenter initiative designed to improve quality of care for patients with common cardiovascular diseases such as Acute Coronary Syndrome ACS, heart failure, and atrial fibrillation. EuroHeart collects standardized and harmonized patient data to support continuous quality improvement by monitoring adherence to quality indicators defined by the European Society of Cardiology ESC. The program aims to understand how well proven treatments are applied in everyday clinical practice. The study involves continuous data collection from consecutive patients hospitalized or treated for these cardiovascular conditions. Participants enter a 12-month follow-up period during which clinical events and health status data are gathered. This registry specifically evaluates adherence to ESC quality indicators in Italian clinical practice, including measures such as time to reperfusion and prescription of recommended medications at discharge. Participants will be monitored through regular collection of clinical data over the 12 months following enrollment. Researchers will assess adherence to multiple ESC quality indicators related to treatment and management of STEMI and NSTEMI patients, including evaluations of left ventricular function, lipid levels, and use of dual antiplatelet therapy and other medications. The study also tracks cardiovascular and non-cardiovascular events during follow-up to support quality improvement efforts. Participation involves consent and data collection without experimental treatments.

Age: 18Years +All Genders
57 locations
F

Actively Recruiting

Researchers are conducting an ongoing international observational program called the Fabry Registry to track routine clinical outcomes in patients diagnosed with Fabry disease. This registry includes all patients regardless of their treatment status and aims to improve understanding of the diseases variability, progression, and natural history, including in female patients. It also supports development of monitoring recommendations, characterization of the Fabry population, and evaluation of the long-term safety and effectiveness of Fabrazyme4. The study features a Fabry Pregnancy Sub-registry, which observes pregnancy outcomes in women enrolled in the main registry. This sub-registry collects data on medical and obstetric history, pregnancy, birth outcomes, and infant growth up to 36 months postpartum. Neither the main registry nor the pregnancy sub-registry involve experimental interventions, and patients receive standard care as determined by their treating physicians. Participants undergo clinical assessments and receive their usual care during the registry. Data collected includes safety and effectiveness of treatments like Fabrazyme4 over long periods, as well as pregnancy complications and infant growth measurements. The study is designed to last until 2034, with ongoing monitoring and data collection to support patient care and research without altering treatment plans.

All AgesAll Genders
284 locations
U

Actively Recruiting

This research investigates the real-world use of the HeartInsight algorithm, designed to predict acute heart failure events in patients with implanted Biotronik ICD or CRT-D devices that have atrial sensing and Home Monitoring capabilities. Heart failure is a serious condition with high rates of hospitalizations and healthcare costs. The HeartInsight algorithm, validated in previous studies, monitors trends in seven physiological parameters to provide early warnings about worsening heart failure, aiming to improve patient management by alerting healthcare providers well in advance. Patients enrolled in this prospective, multicenter observational registry will be followed for 12 months across approximately 14 centers in Italy. The study does not require additional diagnostic tests beyond standard care. When HeartInsight issues an alert, a standardized workflow guides clinical responses such as device adjustments, therapy changes, or extra visits. Patients may also choose to use the HeartInsight Patient App to assist in monitoring. The study collects data on how often alerts occur, the clinical actions taken, patient interviews, and hospitalizations. Participants will have their device data remotely monitored and attend regular clinical visits as part of routine care. Researchers will track the proportion of alerts that lead to clinical actions and measure secondary outcomes like alert frequency, duration of alert periods, patient interviews, hospitalizations, and app usage. Data are collected securely via electronic forms and monitored for quality. The study aims to provide insights into integrating predictive monitoring tools into everyday practice to potentially enhance heart failure care over a 12-month period.

Age: 18Years +All Genders
13 locations
O

Actively Recruiting

Researchers are conducting a multicenter observational study to collect clinical and biological data from patients newly diagnosed with chronic lymphocytic leukemia CLL, small lymphocytic lymphoma SLL, or CLL-like monoclonal B-cell lymphocytosis MBL. The study includes both retrospective and prospective cohorts to better understand diagnosis and management patterns of these conditions over time. The retrospective cohort gathers data from patients diagnosed between January 1, 2010, and August 31, 2021, while the prospective cohort includes those diagnosed from September 1, 2021, through September 1, 2025. Data collection is done through an electronic case report form accessible to participating centers on a dedicated platform. This design allows for comprehensive data analysis across multiple centers in Italy. Participants data will be analyzed to describe diagnosis and management practices at one year for the prospective cohort and at four years for the retrospective cohort. The study involves no treatment administration instead, it focuses on observational data collection. Patient involvement is limited to consent for data use, and researchers monitor clinical and biological information recorded during routine care. The study is sponsored by the Gruppo Italiano Malattie EMatologiche dellAdulto GIMEMA.

Age: 18Years +All Genders
24 locations